Berger Financial Group Inc Has $7.32 Million Holdings in Johnson & Johnson (NYSE:JNJ)

Berger Financial Group Inc raised its holdings in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 2.2% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 41,228 shares of the company’s stock after purchasing an additional 889 shares during the period. Johnson & Johnson accounts for approximately 1.1% of Berger Financial Group Inc’s holdings, making the stock its 22nd biggest holding. Berger Financial Group Inc’s holdings in Johnson & Johnson were worth $7,318,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its position in shares of Johnson & Johnson by 1.4% in the 1st quarter. Vanguard Group Inc. now owns 238,141,110 shares of the company’s stock valued at $42,205,749,000 after acquiring an additional 3,358,478 shares during the period. BlackRock Inc. raised its position in shares of Johnson & Johnson by 0.4% in the 1st quarter. BlackRock Inc. now owns 200,799,189 shares of the company’s stock valued at $35,587,638,000 after acquiring an additional 777,837 shares during the period. Wellington Management Group LLP raised its position in shares of Johnson & Johnson by 0.8% in the 1st quarter. Wellington Management Group LLP now owns 32,772,594 shares of the company’s stock valued at $5,808,286,000 after acquiring an additional 265,330 shares during the period. Bank of New York Mellon Corp raised its position in shares of Johnson & Johnson by 1.6% in the 1st quarter. Bank of New York Mellon Corp now owns 32,070,396 shares of the company’s stock valued at $5,683,837,000 after acquiring an additional 509,818 shares during the period. Finally, Charles Schwab Investment Management Inc. raised its position in shares of Johnson & Johnson by 1.9% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 17,189,229 shares of the company’s stock valued at $3,046,449,000 after acquiring an additional 328,297 shares during the period. 68.59% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Johnson & Johnson

In related news, EVP Kathryn E. Wengel sold 16,410 shares of the firm’s stock in a transaction on Wednesday, November 9th. The shares were sold at an average price of $173.42, for a total value of $2,845,822.20. Following the completion of the transaction, the executive vice president now directly owns 71,311 shares of the company’s stock, valued at $12,366,753.62. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other Johnson & Johnson news, insider William Hait sold 15,000 shares of the firm’s stock in a transaction on Monday, October 24th. The stock was sold at an average price of $171.55, for a total transaction of $2,573,250.00. Following the completion of the sale, the insider now owns 80,236 shares of the company’s stock, valued at approximately $13,764,485.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Kathryn E. Wengel sold 16,410 shares of the firm’s stock in a transaction on Wednesday, November 9th. The shares were sold at an average price of $173.42, for a total value of $2,845,822.20. Following the sale, the executive vice president now directly owns 71,311 shares of the company’s stock, valued at approximately $12,366,753.62. The disclosure for this sale can be found here. Over the last three months, insiders sold 118,795 shares of company stock valued at $20,230,174. 0.35% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. Citigroup cut their price target on shares of Johnson & Johnson from $201.00 to $198.00 in a research report on Wednesday, October 5th. SVB Leerink lowered their target price on Johnson & Johnson from $200.00 to $194.00 in a research note on Wednesday, July 20th. StockNews.com started coverage on Johnson & Johnson in a research note on Wednesday, October 12th. They set a “strong-buy” rating for the company. UBS Group lowered their target price on Johnson & Johnson from $185.00 to $180.00 in a research note on Thursday, July 21st. Finally, Morgan Stanley lowered their target price on Johnson & Johnson from $174.00 to $170.00 and set an “equal weight” rating for the company in a research note on Wednesday, October 19th. Six investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Johnson & Johnson has a consensus rating of “Moderate Buy” and an average price target of $184.25.

Johnson & Johnson Price Performance

Shares of JNJ opened at $173.46 on Thursday. The stock has a market capitalization of $453.51 billion, a P/E ratio of 24.16, a P/E/G ratio of 3.35 and a beta of 0.57. Johnson & Johnson has a twelve month low of $155.72 and a twelve month high of $186.69. The company has a 50 day moving average of $167.44 and a 200-day moving average of $171.39. The company has a quick ratio of 1.18, a current ratio of 1.43 and a debt-to-equity ratio of 0.37.

Johnson & Johnson (NYSE:JNJGet Rating) last released its earnings results on Tuesday, October 18th. The company reported $2.55 earnings per share for the quarter, beating the consensus estimate of $2.49 by $0.06. Johnson & Johnson had a net margin of 19.95% and a return on equity of 35.37%. The business had revenue of $23.79 billion during the quarter, compared to analysts’ expectations of $23.44 billion. During the same period last year, the business earned $2.60 earnings per share. The firm’s revenue was up 1.9% on a year-over-year basis. As a group, equities research analysts forecast that Johnson & Johnson will post 10.04 EPS for the current fiscal year.

Johnson & Johnson announced that its Board of Directors has initiated a stock repurchase plan on Wednesday, September 14th that allows the company to buyback $5.00 billion in shares. This buyback authorization allows the company to buy up to 1.2% of its shares through open market purchases. Shares buyback plans are generally a sign that the company’s board of directors believes its stock is undervalued.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 6th. Investors of record on Tuesday, November 22nd will be paid a $1.13 dividend. The ex-dividend date of this dividend is Monday, November 21st. This represents a $4.52 annualized dividend and a dividend yield of 2.61%. Johnson & Johnson’s dividend payout ratio is presently 62.95%.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Recommended Stories

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.